Program
MVA-BN smallpox vaccine
Also written as “IMVAMUNE”, “IMVAMUNE (MVA-BN)” and “IMVAMUNE®”.
Its studies are mostly in Smallpox · Mpox, Monkeypox · Dermatitis, Atopic · HIV Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bavarian Nordic | 142 open or running | phase 4since Mar 5, 2018 | Sep 11, 2005 | Nov 30, 2026phase 2 · NCT07199569 |
| Johnson & Johnson | 10 open or running | early phase 1since Apr 1, 2019 | Apr 1, 2019 | none ahead |
| Sanofi | 10 open or running | phase 2since Apr 25, 2007 | Apr 25, 2007 | none ahead |
Also a collaborator on its studies: ICON.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2005First studies: 2 phase 2 studiesNew to Bavarian NordicBavarian Nordic · NCT00189956, NCT00189904
- Sep 11, 20052 phase 1 studiesBavarian Nordic · NCT00189917, NCT00189943
- Apr 19, 20063 phase 2 studiesBavarian Nordic · NCT00316589, NCT00316524, NCT00316602
- Apr 25, 2007Sanofi’s first study: phase 2 study in SmallpoxNew to SanofiSanofi · NCT00466245 · 590 enrolled
- May 27, 2008Phase 2 study in SmallpoxBavarian Nordic · NCT00686582 · 304 enrolled · Germany
- Mar 5, 2009Phase 2 study in SmallpoxBavarian Nordic · NCT00857493 · 120 enrolled · United States
- Jun 14, 2010Phase 3 study in SmallpoxBavarian Nordic · NCT01144637 · 4,005 enrolled · United States
- Jan 15, 2014Phase 2 study in SmallpoxBavarian Nordic · NCT02038881 · 87 enrolled · United States, Puerto Rico
- Mar 5, 2018Phase 4 study in VaccinationBavarian Nordic · NCT03472014 · 22 enrolled · United States
- Apr 1, 2019Johnson & Johnson’s first study: early phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT03953196 · 48 enrolled · Belgium
- Jul 31, 2024Phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT06549530 · 460 enrolled · Democratic Republic of the Congo, Uganda
- Sep 22, 2025Phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT07199569 · 970 enrolled · United States
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT07199569
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, ”NCIt, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07199569Mpox, Monkeypox · United States | 2 | Active, not recruiting | Bavarian Nordic | Nov 30, 2026 | 970 |
| NCT06549530Mpox, Monkeypox · Democratic Republic of the Congo, Uganda | 2 | Active, not recruiting | Bavarian Nordic | May 1, 2026 | 460 |
| NCT03953196Healthy · Belgium | Early 1 | Completed | Johnson & Johnson | Dec 26, 2019 | 48 |
| NCT03472014Vaccination · United States | 4 | Completed | Bavarian Nordic | Nov 14, 2014 | 22 |
| NCT02038881Smallpox · United States, Puerto Rico | 2 | Completed | Bavarian Nordic | May 10, 2017 | 87 |
| NCT01144637Smallpox · United States | 3 | Completed | Bavarian Nordic | Nov 2013 | 4,005 |
| NCT00857493Smallpox · United States | 2 | Completed | Bavarian Nordic | Aug 2010 | 120 |
| NCT00686582Smallpox · Germany | 2 | Completed | Bavarian Nordic | Dec 2008 | 304 |
| NCT00466245Smallpox | 2 | Completed | Sanofi | Jun 2006 | 590 |
| NCT00316602Dermatitis, Atopic · United States, Mexico | 2 | Completed | Bavarian Nordic | Nov 2009 | 632 |
| NCT00316589HIV Infections · United States, Puerto Rico | 2 | Completed | Bavarian Nordic | Mar 2009 | 581 |
| NCT00316524Smallpox · Germany | 2 | Completed | Bavarian Nordic | Feb 2007 | 745 |
| NCT00189943Smallpox · Germany | 1 | Completed | Bavarian Nordic | 90 | |
| NCT00189956Smallpox · Switzerland | 2 | Completed | Bavarian Nordic | Nov 2003 | 165 |
| NCT00189917Dermatitis, Atopic · Germany | 1 | Completed | Bavarian Nordic | Dec 2005 | 60 |
| NCT00189904HIV Infections · United States | 2 | Completed | Bavarian Nordic | 151 |
How it is read
Names in the registry
- “IMVAMUNE”, 5 entries
- “IMVAMUNE (MVA-BN)”, 4 entries
- “IMVAMUNE®”, 3 entries
- “MVA-BN”, 2 entries
- “MVA-BN (Quail)”, 1 entry
Conditions, from the studies’ own filings
- Smallpox, 8 studies
- Mpox, Monkeypox, 2 studies
- Dermatitis, Atopic, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.